Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and -independent pathways in rat liver

Hepatology

Volumn 44, Issue 5, 2006, Pages 1206-1217

  Graf, Dirk ^a   Kohlmann, Caroline ^a   Haselow, Katrin ^a   Gehrmann, Thor ^a   Bode, Johannes G ^a   Häussinger, Dieter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; CASPASE 3; CELL EXTRACT; FAS ANTIGEN; GLYCOCHENODEOXYCHOLIC ACID; GLYCOPROTEIN; GLYCOPROTEIN GP 130; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN GP 80; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HYDROPHOBICITY; HYPEROSMOLALITY; IMMUNOREACTIVITY; LIVER CELL; LIVER PERFUSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; STRESS;

ANIMALS; BILE ACIDS AND SALTS; CASPASES; CELL LINE; CELLS, CULTURED; CYTOKINE RECEPTOR GP130; DOWN-REGULATION; GLYCOCHENODEOXYCHOLIC ACID; HEPATOCYTES; INTERLEUKIN-6; LIVER; MALE; ORGANIC ANION TRANSPORTERS, SODIUM-DEPENDENT; PHOSPHORYLATION; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SYMPORTERS;

EID: 33750970321     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21368     Document Type: Article

References (50)

1. Barton BE. The biological effects of interleukin-6. Med Res Rev 1996;16:87-109.
2. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003;374:1-20.
3. Pflanz S, Hibbert L, Mattson J, Rosales R, Vaisberg E, Bazan JF, et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004;172:2225-2316.
4. Hong F, Wim WH, Tian Z, Jaruga B, Ishac E, Shen X, et al. Elevated interleukin-6 during ethanol consumption acts as a potential endogenous protective cytokine against ethanol-induced apoptosis in the liver: involvement of induction of Bcl-2, and Bcl-x (L) proteins. Oncogene 2002;21:32-43.
5. Kovalovich K, DeAngelis RA, Li W, Furth EE, Ciliberto G, Taub G. Increased toxin-induced liver injury and fibrosis in interleukin-6-deficient mice. HEPATOLOGY 2000;31:149-159.
6. Camargo CA, Madden JF, Gao W, Selvan RS, Clavien PA. Interleukin-6 protects liver against warm ischemia/reperfusion injury and promotes hepatocyte proliferation in the rodent. HEPATOLOGY 1997;26:1513-1520.
7. Kimura F, Miyazaki M, Suwa T, Sugiura T, Shinoda T, Itoh H, et al. Serum interleukin-6 levels in patients with biliary obstruction. Hepatogastroenterology 1999;46:1613-1617.
8. Sewnath ME, van der Poll T, van Noorden CJF, ten Kate FJW, Gouma DJ. Cholestatic interleukin-6 deficient mice succumb to endotoxin-induced liver injury and pulmonary inflammation. Am J Respir Crit Care Med 2004;169:413-420.
9. Streetz KL, Wuestefeld T, Klein C, Kallen KJ, Tronche F, Betz UA, et al. Lack of gp130 expression in hepatocytes promotes liver cell injury. Gastroenterology 2003:125:532-543.
10. Cressman DE, Greenbaum LE, Deangilis RA, Ciliberto G, Furth EE, Poli V, et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996;274:1379-1383.
11. Ezure T, Sakamoto T, Tsuji H, Lunz JG, Murase N, Fung JJ, et al. The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am J Pathol 2000;156:1627-1639.
12. Wuestefeld T, Klein C, Streetz KL, Beraza N, Schölmerich J, Burgart LJ, et al. Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice. HEPATOLOGY 2005;42:1082-1090.
13. Streetz KL, Tacke F, Leifeld L, Wuestefeld T, Graw A, Klein C, et al. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. HEPATOLOGY 2003;38:218-229.
14. Graf D, Kurz AK, Fischer R, Reinehr R, Häussinger D. Taurolithocholic acid-3 sulfate induces CD95 trafficking and apoptosis in a c-Jun N-terminal kinase dependent manner. Gastroenterology 2002;122:1411-1427.
15. Sodeman T, Bronk SF, Roberts PJ, Miyoshi H, Gores GJ. Bile salts mediate hepatocyte apoptosis by increasing cell surface trafficking of Fas. Am J Physiol Gastrointest Liver Physiol 2000;278:992-999.
16. Reinehr R, Graf D, Häussinger D. Bile salt-induced hepatocyte apoptosis involves epidermal growth factor receptor-dependent CD95 tyrosine phosphorylation. Gastroenterology 2003;125:839-853.
17. Reinehr R, Becker S, Wettstein M, Häussinger D. Involvement of the src family kinase yes in bile salt-induced apoptosis. Gastroenterology 2004;127:1540-1547.
18. Reinehr R, Becker S, Keitel V, Eberle A, Grether-Beck S, Haussinger D. Bile salt-induced apoptosis involves NADPH oxidase isoform activation. Gastroenterology 2005;129:2009-2031.
19. Rodrigues CM, Fan G, Wong PY, Kren BT, Steer CJ. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol Med 1998;4:165-178.
20. Yerushalmi B, Dahl R, Devereaux MW, Gumpricht E, Sokol RJ. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. HEPATOLOGY 2001;33:616-626.
21. Jones BA, Rao YP, Stravitz RT, Gores GJ. Bile salt-induced apoptosis of hepatocytes involves activation of protein kinase C. Am J Physiol 1997;272:G1109-G1115.
22. Kurz AK, Graf D, Schmitt M, vom Dahl S, Häussinger D. Tauroursodesoxy-cholate-induced choleresis involves p38(MAPK) activation and translocation of the bile salt export pump in rats. Gastroenterology 2001;121:407-419.
23. Schliess F, Kurz AK, vom Dahl S, Häussinger D. Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver. Gastroenterology 1997;113:1306-1314.
24. Beuers U, Bilzer M, Chittartu A, Kullak-Ublick GA, Keppler D, Paumgartner G, et al. Tauroursodeoxycholic acid inserts the apical conjugate export pump, Mrp2, into canalicular membranes and stimulates organic anion secretion by protein kinase C-dependent mechanisms in cholestatic rat liver. HEPATOLOGY 2001;33:1206-1216.
25. Kurz AK, Block C, Graf D, vom Dahl S, Schliess F, Häussinger D. Phosphoinositide 3-kinase-dependent Ras activation by tauroursodesoxycholate in rat liver. Biochem J 2000;350:207-213.
26. 2+ signals in isolated rat hepatocytes. Gastroenterology 1993:104:604-612.
27. Bouscarel B, Ceryak S, Gettys TW, Fromm H, Noonan F. Alteration of cAMP-mediated hormonal responsiveness by bile acids in cells of nonhepatic origin. Am J Physiol 1995;268:G908-G916.
28. +-taurocholate cotransporting green fluorescent protein in human hepatoblastome HepG2 cells. Cytotechnology 2000;34:1-9.
29. Lang R, Heeg K. Semiquantitative determination of human cytokine mRNA expression using TaqMan RT-PCR. Inflammopharmacology 1998;6:297-309.
30. Bae SS, Choi JH, Oh YS, Perry DK, Ryu SH, Suh P. Proteolytic cleavage of epidermal growth factor receptor by caspases. FEBS Lett 2001;491:16-20.
31. Krebs DL, Hilton DJ. SOCS proteins: negative regulators of cytokine signalling. Stem Cells 2001;19:378-387.
32. Bode JG, Ludwig S, Correia Freitas CA, Schaper F, Ruhl M, Melmed S, et al. The MKK6/p38 mitogen-activated protein kinase pathway is capable of inducing SOCS3 gene expression and inhibits IL-6-induced transcription. Biol Chem 2001;382:1447-1453.
33. Bode JG, Nimmesgern A, Schmitz J, Schaper F, Schmitt M, Frisch W, et al. LPS and TNF-α induce SOCS3 mRNA and inhibit IL-6-induced activation of STAT3 in macrophages. FEBS Lett 1999;463:365-370.
34. Siewert E, Müller-Esterl W, Starr R, Heinrich PC, Schaper F. Different protein turnover of interleukin-6-type cytokine signaling components. Eur J Biochem 1999;265:251-257.
35. Blanchard F, Wang Y, Kinzie E, Duplomb L, Godard A, Baumann H. Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor α, and oncostatin M receptor β by distinct mechanisms. J Biol Chem 2001;276:47038-47045.
36. Graeve L, Korolenko TA, Hemmann U, Weiergraeber O, Dittrich E, Heinrich PC. A complex of the soluble interleukin-6 receptor and interleukin-6 is internalized via the signal transducer gp130. FEBS Lett 1996;399:131-134.
37. Reinehr R, Graf D, Fischer R, Schliess F, Haussinger D. Hyperosmolarity triggers CD95 membrane trafficking and sensitizes rat hepatocytes toward CD95L-induced apoptosis. HEPATOLOGY 2002;36:602-614.
38. Fischer U, Jänicke RU, Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ 2003;10:76-100.
39. He YY, Huang JL, Gentry JB, Chignell CF. Epidermal growth factor receptor down-regulation induced by UVA on human keratinocytes does not require the receptor kinase activity. J Biol Chem 2003;278:42457-42465.
40. Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsaides C, et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signalling cascades via caspase-dependent down-regulation of gp130 in multiple myeloma. Oncogene 2003;22:8386-8393.
41. Bode JG, Schweigart J, Kehrmann J, Ehlting C, Schaper F, Heinrich PC, et al. TNF-α induces tyrosine phosphorylation and recruitment of the src homology protein-tyrosine phosphatase 2 to the gp130 signal-transducing subunit of the IL-6 receptor complex. J Immunol 2003;170:257-266.
42. Bode JG, Fischer R, Häussinger D, Graeve L, Heinrich PC, Schaper F. The inhibitory effect of IL-1 beta on IL-6-induced alpha 2-macroglobulin expression is due to activation of NF-kappa B. J Immunol 2001;167:1469-1481.
43. Ahmed ST, Ivashkiv LB. Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways. J Immunol 2000;165:5227-5237.
44. Hirano T, Ishihara K, Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 2000;19:2548-2556.
45. Quintanilla-Martinez L, Kremer M, Specht K, Calzada-Wack J, Nathrath M, Schaich R, et al. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. Am J Pathol 2003;162:1449-1461.
46. Blindenbacher A, Wang X, Langer I, Savino R, Terracciano L, Heim MH. Interleukin 6 is important for survival after partial hepatectomy in mice. HEPATOLOGY 2003;38:674-682.
47. Wustefeld T, Rakemann T, Kubicka S, Manns MP, Trautwein C. Hyperstimulation with interleukin 6 inhibits cell cycle progression after hepatectomy in mice. HEPATOLOGY 2000;32:514-522.
48. Mann DV, Lam WWM, Hjelm NM, So NMC, Yeung DKW, Metreweli C, et al. Human liver regeneration: hepatic energy economy is less efficient when the organ is diseaded. HEPATOLOGY 2001;34:557-565.
49. Kimmings AN, van Deventer SJ, Obertop H, Rauws EA, Huibregtse K, Gouma DJ. Endotoxin, cytokines, and endotoxin binding proteins in obstructive jaundice and after preoperative biliary drainage. Gut 2000; 46:725-731.
50. Nakano H, Fujiwara Y, Kitamura N, Kumada K, Matsumiya A, Sakai H, et al. Susceptibility to lipopolysaccharide of cholestatic rat liver produced with bile duct ligation: assessments of the mitochondrial glutathione pool and the effects of N-acetylcysteine. Eur Surg Res 2000;32:148-154.